ZAI LAB LIMITED Proceeds from Sale of Intangible Assets
ZAI LAB LIMITED (ZLAB) reported Proceeds from Sale of Intangible Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2026-02-26
- ZAI LAB LIMITED proceeds from sale of intangible assets for the quarter ending 2024-12-31 was $0.00.
- ZAI LAB LIMITED proceeds from sale of intangible assets for the quarter ending 2024-09-30 was $0.00.
- ZAI LAB LIMITED proceeds from sale of intangible assets for the quarter ending 2023-12-31 was $0.00.
- ZAI LAB LIMITED proceeds from sale of intangible assets for the quarter ending 2023-09-30 was $0.00.
- ZAI LAB LIMITED proceeds from sale of intangible assets for fiscal 2025 was $0.00.
- ZAI LAB LIMITED proceeds from sale of intangible assets for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ZAI LAB LIMITED proceeds from sale of intangible assets for fiscal 2023 was $10.00M.
- ZAI LAB LIMITED proceeds from sale of intangible assets for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 6 month | Proceeds from Sale of Intangible Assets 9 month | Proceeds from Sale of Intangible Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $10.00M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $10.00M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $10.00M 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |